ArticleCancer science2022
An oral first-in-class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer.
Miho Ushijima et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
15 papers cite it
this papercites it